Heterogeneity of epidermal growth factor receptor mutations in lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements: A case report

摘要: Lung cancer is a heterogeneous and complex disease that remains the leading cause of cancer-related mortality worldwide. The identification epidermal growth factor receptor (EGFR) mutation anaplastic lymphoma kinase (ALK) rearrangements has changed treatment non-small cell lung cancer, creating personalized era based on appropriate molecular selection patients. In spite efficacy tyrosine inhibitors (TKIs), acquired resistance inevitable due to various mechanisms. present study reports case 30-year-old patient with stage IV adenocarcinoma initially harboring an EGFR mutation. However, following progression series treatments, wild-type gene was observed ALK were revealed. Erlotinib administration resulted in good response initially, but crizotinib did not. This indicated association between secondary mutations kinases drug TKIs. should also highlight clinical significance repeat biopsies for subsequent therapeutic choices at onset progression.